Halozyme reports 39% revenue growth and raises 2026 guidance with strong royalty gains and new collaborations.

Halozyme Therapeutics reported a 39% year-over-year revenue increase to $493 million in Q3 2026, driven by a 44% rise in royalty revenue to $341 million. The company expanded its ENHANZE® collaboration agreements and advanced three programs into Phase 1 clinical development, signaling growth in its drug delivery platform. Halozyme also won a patent infringement case against Merck in Europe, protecting its intellectual property. Based on strong performance, Halozyme raised its full-year 2026 financial guidance, expecting total revenue of $1.86-$1.93 billion and adjusted EBITDA growth near 90%.

Halozyme Therapeutics shares are trading at USD 115.50, down 11.39% as of Nov 06, 2026 04:11 WIB on Pluang, despite the company raising its full-year financial guidance. The stock's market cap stands at $14.80 billion with a 52-week high of $131.18. Meanwhile, Merck shares also declined 2.26% to USD 146.94, with a market cap of $370.96 billion, reflecting broader sector movements.